Keywords: nexium, tops, rival, gerd, maintenance, trial, astrazeneca
Nexium tops rival in GERD maintenance trial
Article | 04 March 2002
AstraZeneca's new-generation proton pump inhibitor Nexium(esomeprazole), the follow-up to its best-selling Losec/Prilosec (omeprazole) drug, has been shown to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
